Literature DB >> 10696101

Possible mechanisms underlying the vasodilatation induced by olprinone, a phosphodiesterase III inhibitor, in rabbit coronary artery.

M Ohashi1, Y Dohi, T Itoh.   

Abstract

The possible mechanisms underlying the vasodilatation induced by olprinone, a phosphodiesterase type III inhibitor, were investigated in smooth muscle of the rabbit coronary artery. Isometric force and membrane potential were measured simultaneously using endothelium-denuded smooth muscle strips. Acetylcholine (ACh, 3 microM) produced a contraction with a membrane depolarization (15. 2+/-1.1 mV). In a solution containing 5.9 mM K(+), olprinone (100 microM) hyperpolarized the resting membrane and (i) caused the absolute membrane potential level reached with ACh to be more negative (but did not reduce the delta membrane potential seen with ACh, 15.2+/-1.8 mV) and (ii) attenuated the ACh-induced contraction. In a solution containing 30 mM K(+), these effects were not seen with olprinone. Glibenclamide (10 microM) blocked the olprinone-induced membrane hyperpolarization. 4-AP (0.1 mM) significantly attenuated the olprinone-induced resting membrane hyperpolarization but TEA (1 mM) had no such effect. Glibenclamide (10 +microM), TEA (1 mM) and 4-AP (0.1 mM), given separately, all failed to modify the inhibitory actions of olprinone on (i) the absolute membrane potential level seen with ACh and (ii) the ACh-induced contraction. It is suggested that olprinone inhibits the ACh-induced contraction through an effect on the absolute level of membrane potential achieved with ACh in smooth muscle of the rabbit coronary artery. It is also suggested that glibenclamide-sensitive, ATP-sensitive K(+) channels do not play an important role in the olprinone-induced inhibition of the ACh-induced contraction.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10696101      PMCID: PMC1571910          DOI: 10.1038/sj.bjp.0703125

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  18 in total

1.  Effect of a novel inhibitor of cyclic AMP phosphodiesterase, E-1020, on cytosolic Ca++ level and contraction in vascular smooth muscle.

Authors:  M Tajimi; H Ozaki; K Sato; H Karaki
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-11       Impact factor: 3.000

2.  Activation of ATP-sensitive K+ channels by cyclic AMP-dependent protein kinase in cultured smooth muscle cells of porcine coronary artery.

Authors:  H Miyoshi; Y Nakaya
Journal:  Biochem Biophys Res Commun       Date:  1993-05-28       Impact factor: 3.575

3.  Effects of E-1020, a new cyclic AMP-specific phosphodiesterase inhibitor, on cyclic AMP and cytosolic free calcium of cultured vascular smooth muscle cells.

Authors:  M Ohoka; M Honda; S Morioka; S Ishikawa; K Nakayama; Y Yamori; K Moriyama
Journal:  Jpn Circ J       Date:  1990-06

4.  Mechanisms responsible for forskolin-induced relaxation of rat tail artery.

Authors:  C M Rembold; X L Chen
Journal:  Hypertension       Date:  1998-03       Impact factor: 10.190

5.  Cardiovascular effects of the new cardiotonic agent 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridin-6-yl)-3-pyridine carbonitrile hydrochloride monohydrate. 1st communication: studies on isolated guinea pig cardiac muscles.

Authors:  T Ogawa; H Ohhara; H Tsunoda; J Kuroki; T Shoji
Journal:  Arzneimittelforschung       Date:  1989-01

6.  Effects of a water-soluble forskolin derivative (NKH477) and a membrane-permeable cyclic AMP analogue on noradrenaline-induced Ca2+ mobilization in smooth muscle of rabbit mesenteric artery.

Authors:  S Ito; S Suzuki; T Itoh
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

7.  Ca2+(-)dependent and Ca2+(-)independent vasorelaxation induced by cardiotonic phosphodiesterase inhibitors.

Authors:  H Itoh; M Kusagawa; A Shimomura; T Suga; M Ito; T Konishi; T Nakano
Journal:  Eur J Pharmacol       Date:  1993-08-10       Impact factor: 4.432

8.  Comparison of the effects on arterial-ventricular coupling between phosphodiesterase inhibitor and dobutamine in the diseases human heart.

Authors:  H Takaoka; M Takeuchi; M Odake; Y Hayashi; M Mori; K Hata; M Yokoyama
Journal:  J Am Coll Cardiol       Date:  1993-08       Impact factor: 24.094

9.  Identification and characterization of isoenzymes of cyclic nucleotide phosphodiesterase in human kidney and heart, and the effects of new cardiotonic agents on these isoenzymes.

Authors:  M Sugioka; M Ito; H Masuoka; K Ichikawa; T Konishi; T Tanaka; T Nakano
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-09       Impact factor: 3.000

10.  Isoproterenol causes hyperpolarization through opening of ATP-sensitive potassium channels in vascular smooth muscle of the canine saphenous vein.

Authors:  M Nakashima; P M Vanhoutte
Journal:  J Pharmacol Exp Ther       Date:  1995-01       Impact factor: 4.030

View more
  2 in total

1.  Reduced function of endothelial prostacyclin in human omental resistance arteries in pre-eclampsia.

Authors:  Yoshikatsu Suzuki; Tomonori Hattori; Junko Kajikuri; Tamao Yamamoto; Kaoru Suzumori; Takeo Itoh
Journal:  J Physiol       Date:  2002-11-15       Impact factor: 5.182

2.  Characterization of changes in mechanical responses to histamine in omental resistance arteries in pre-eclampsia.

Authors:  Y Suzuki; M Saitoh; K Suzumori; J Kajikuri; T Itoh
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.